able on Hugh. ongoing for to Thanks, update this you be INNATE our provide an I'm to morning study. pleased
combination both pimivalimab, Phase As monotherapy as both X expansion monotherapy a inhibitor, in and for and X with different the Phase cohort PD-X selected our for reminder, we XXX initiated treatment completed X combination indications. dose dose pimi, seven and milligrams recommended escalation the in Phase the
data. We Dose the this and INNATE data data that have be at ESMO-IO Phase in December. escalation as X announced include conference efficacy poster presented will year's safety, PK, occupancy a preliminary receptor will
remain to the engaged. investigators study INNATE on very We well continue and execute
completed first in cohort of have nearing in one the We of patients Phase enrollment the and enrollment X of Phase cancer. XX one in current are cohorts all of stage stage completion ovarian combination monotherapy X
enrollment ovarian enrolling, and after we patients ovarian monotherapy the quickly combination pick cohort not the were was combination being arm in we were the to see completed up pleased While enrolled enrollment. this again
additional naive in PD-X-inhibitor today have inhibitor line PD-X cancer. announcing resistant third inhibitor ovarian expand to met PD-X our and renal types second of head to criteria tumor addition announced an resistant in previously and neck we that and cohort We the are cancer,
design, sarcoma not cohort, from of meet carcinoma, one combo combo inhibitor naive to a with two cancer have advance stage we cutaneous in PD-X In to neck the for resistant JTX-XXXX potential cohort to drug. differentiated to pimi. avoid cell frequent goal In in opportunity criteria clinically patient combination enrollment provide see line from a potential in to two. we combination October in approved inhibitor in expansion. pimi. or one first BTC. assignments in And resistant stage response two. and the been a like did in first today, monotherapy biliary PD-X line inhibitor inhibitor we for addition, Furthermore, advance and one announced to stage resistant BTC the our resistant to plus inhibitor with with stage in The X response resistant to recently more still first patients In confirmed internal inhibitor new still cohort and potentially on squamous in XX stage meaningful cell and, durable remaining on to PD-X the would in in as chemotherapy active Durvalumab X the Phase lung cohorts details criteria is PD-X our stage non-small questions, has ovarian stage inhibitor tract a based head meet naive a along started cancer PD-X one BTC PD-X rejecting cancers PD-X cohorts criteria
we the So, of the bar assignments to stage, side. as set on the first stage low in typical,
single monotherapy one or least and small expected appropriate, requires Our XX% rate for criteria greater PD-X the rate, the the in are to from first our expand each inhibitor response cohorts exception most fact two internal unconfirmed, size criteria of is neck confirmed to the the in decision with a at stage We believe digits. response is response stage that sample given or for line the a rate. XX% cohort, which and combo cohort head
additional prior duration best INNATE. response In numerical meeting therapy, and criteria, factors, to consider prior response addition the since time size the such as the and the the at we to overall in quality therapy, tumor of baseline, the elapsed response
data second in in with met although we're based concept numerical we have cohort the in requires deciding criteria before response expand. For the inhibitor confidence benchmarks. is and PD-X patients additional to response responses and excludes and expanded qualitative Proof interval the a cohort, on neck for that confirmed an XX whether full example, line head rate a third the of waiting
one XXXX, is week time week reductions less cancer become the The which taking is XX renal important XX cohorts nine Moving data XX confirmation for expansion. previously at that over weeks. patients disease XX, expansion criteria has Consistent stage enrolled completion on of XX the near with study to the Merck's enrolled. stable is met patients efficacy potential published in for with data it out data INNATE with to have far that our so renal observation at combination and patients ovarian ovarian in means expansion mature. An XX% wait at to than tumor then we with from least responders January to MK-XXXX seen until and
develop weeks weeks confirmed responses, responses In nine patients new XX due have pseudo lesions at with inhibitor one lung pathologically resistant addition and non-small progressive at to PD-X have in cell progression case disease confirmed we of observed seen cancer. partial to
with broad that selection its be to therapy in that combination of ensure in not inhibitor to we report any these prior to may possibility a of the require PD-X or patients biomarker be We for new data. have but we rapid results inherent believe history. seen we significant or of preliminary combination all responses may These for of the date activity of inhibitor summary, may over leading importance mature. activity we tumor a confirmed JTX-XXXX, with reflect time proof observations, to result the includes signs kinetics, additional a own also and and clinical especially waiting of LILRBX As mechanism concept. have across the data In the in XX raise cohorts, believe more enough specific efficacy in data to enrichment aim patients
the data depend we able sufficiently we and expect subsequent will the data to prior interpretable. full data cohorts those we first that interpretation. be such and clinical initial is emphasize consistent way. with in and present We enrollment be timing cohorts, of today, We as will that meaningful biomarker want require one that the then be INNATE data This in whether share and the the stage assess and of would on following additional from described stage cohorts, two guidance any to for to to the have eight begins mature when or
of updates on to earnings will We continue on quarterly the calls. study our the progress provide
target X different to vopratelimab timing in will expect the present be be the forum and study first as share study pimi the have pulsatile ESMO-IO. different may cohort for The evaluating determined under XX% complete data would The the pimi alone for I will for doses date that Central XX% results be portion with response pimi in half a Review, We X this the an like at from for with to two we believe you to Phase to versus two agonist encouraging, believe in randomized investigation specific six-month XX% patterns by alone and rate position alone. for XXXX. data dose We also SELECT available results landmark will versus more pimi of the as additional low and of XX.X% engagement, ESMO-IO. which a is combination are survival Independent antibody. SELECT proceeds we versus becomes doses important presented remind progression-free us. Radiology at be to Phase
there biological addition, activity preclinical by with an In engagement target is rationale for and improved data pulsatile agonist.
to the as our OS trust without plan to year inhibitor. of a put of X.XX valued Dimitri. lives. PD-X call progress guide I data biomarker to difference This to reporting investigators, kg development and We we remains of of who not a programs. focus forward we continued to will data and execution the in importantly, with we would in per turn combination pursue to concept mature, patients PFS clinical key And Jounce. look over our the a be mgs the milestones important their on a now partnership our vopra As make here to proof on drugs the team, high of enable our in continued quality, and dedication for further and our collection their most an
